Brentuximab vedotin (Adcetris®)

Assessment Status NCPE Assessment Process Complete
Drug Brentuximab vedotin
Brand Adcetris®
Indication Treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant  or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Assessment Process
Rapid review commissioned 28/11/2012
Rapid review completed 21/12/2012
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full submission received from Applicant 16/09/2013
NCPE assessment completed 11/04/2014
NCPE assessment outcome Reimbursement not Recommended

December 2015

The HSE has approved reimbursement following confidential price negotiations.

Technical Summary